US Biosimilars Strength Rides On The Wings Of Oncology Launches
Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.
You may also be interested in...
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.
Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.
Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.